| Dr William Clarence Geisert, MD | |
|
1316 E 7th St, Auburn, IN 46706-2538 | |
| (260) 920-2720 | |
| Not Available |
| Full Name | Dr William Clarence Geisert |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 12 Years |
| Location | 1316 E 7th St, Auburn, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336415736 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 01086351A (Indiana) | Secondary |
| 207X00000X | Orthopaedic Surgery | 4301100411 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Dekalb Health | Auburn, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Parkview Health System Inc | 2163336967 | 1167 |
News Archive
In a session at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, experts discussed the tools required to eradicate the disease and highlighted insecticide and drug resistance in some parts of the world, Xinhua reports. Researchers noted that resistance to artemisinin-based combination therapies (ACTs) has been documented in western Cambodia and "has now also been reported in the west of Thailand and in eastern Myanmar," the news service writes (Ooko/Zhuoyun, 11/5).
The Group of Seven industrialized nations on Friday plans to sign an agreement to provide $1.5 billion to develop vaccines for diseases - including HIV/AIDS, TB and malaria - that largely affect developing countries, the government of Italy announced on Tuesday, Reuters reports.
Research by a Michigan State University cardiologist published in the September edition of Clinical Cardiology has shed new light on the role that cholesterol plays in causing heart attacks, strokes and other cardiovascular events in humans.
Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today positive topline results from a Phase 1 clinical trial for CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations associated with Parkinson's disease.
With nearly $1 million in government funding, University of Rochester scientists are testing a new innovation in biotherapy by altering a common childhood respiratory virus, the adenovirus, to destroy cancer cells.
› Verified 9 days ago
| Entity Name | Parkview Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932130952 PECOS PAC ID: 2163336967 Enrollment ID: O20031117000288 |
News Archive
In a session at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, experts discussed the tools required to eradicate the disease and highlighted insecticide and drug resistance in some parts of the world, Xinhua reports. Researchers noted that resistance to artemisinin-based combination therapies (ACTs) has been documented in western Cambodia and "has now also been reported in the west of Thailand and in eastern Myanmar," the news service writes (Ooko/Zhuoyun, 11/5).
The Group of Seven industrialized nations on Friday plans to sign an agreement to provide $1.5 billion to develop vaccines for diseases - including HIV/AIDS, TB and malaria - that largely affect developing countries, the government of Italy announced on Tuesday, Reuters reports.
Research by a Michigan State University cardiologist published in the September edition of Clinical Cardiology has shed new light on the role that cholesterol plays in causing heart attacks, strokes and other cardiovascular events in humans.
Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today positive topline results from a Phase 1 clinical trial for CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations associated with Parkinson's disease.
With nearly $1 million in government funding, University of Rochester scientists are testing a new innovation in biotherapy by altering a common childhood respiratory virus, the adenovirus, to destroy cancer cells.
› Verified 9 days ago
| Entity Name | Orthopaedics Northeast Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740268796 PECOS PAC ID: 9234024878 Enrollment ID: O20040405001087 |
News Archive
In a session at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, experts discussed the tools required to eradicate the disease and highlighted insecticide and drug resistance in some parts of the world, Xinhua reports. Researchers noted that resistance to artemisinin-based combination therapies (ACTs) has been documented in western Cambodia and "has now also been reported in the west of Thailand and in eastern Myanmar," the news service writes (Ooko/Zhuoyun, 11/5).
The Group of Seven industrialized nations on Friday plans to sign an agreement to provide $1.5 billion to develop vaccines for diseases - including HIV/AIDS, TB and malaria - that largely affect developing countries, the government of Italy announced on Tuesday, Reuters reports.
Research by a Michigan State University cardiologist published in the September edition of Clinical Cardiology has shed new light on the role that cholesterol plays in causing heart attacks, strokes and other cardiovascular events in humans.
Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today positive topline results from a Phase 1 clinical trial for CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations associated with Parkinson's disease.
With nearly $1 million in government funding, University of Rochester scientists are testing a new innovation in biotherapy by altering a common childhood respiratory virus, the adenovirus, to destroy cancer cells.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr William Clarence Geisert, MD 1316 E 7th St, Auburn, IN 46706-2538 Ph: (260) 920-2720 | Dr William Clarence Geisert, MD 1316 E 7th St, Auburn, IN 46706-2538 Ph: (260) 920-2720 |
News Archive
In a session at the 5th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Nairobi, Kenya, experts discussed the tools required to eradicate the disease and highlighted insecticide and drug resistance in some parts of the world, Xinhua reports. Researchers noted that resistance to artemisinin-based combination therapies (ACTs) has been documented in western Cambodia and "has now also been reported in the west of Thailand and in eastern Myanmar," the news service writes (Ooko/Zhuoyun, 11/5).
The Group of Seven industrialized nations on Friday plans to sign an agreement to provide $1.5 billion to develop vaccines for diseases - including HIV/AIDS, TB and malaria - that largely affect developing countries, the government of Italy announced on Tuesday, Reuters reports.
Research by a Michigan State University cardiologist published in the September edition of Clinical Cardiology has shed new light on the role that cholesterol plays in causing heart attacks, strokes and other cardiovascular events in humans.
Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today positive topline results from a Phase 1 clinical trial for CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations associated with Parkinson's disease.
With nearly $1 million in government funding, University of Rochester scientists are testing a new innovation in biotherapy by altering a common childhood respiratory virus, the adenovirus, to destroy cancer cells.
› Verified 9 days ago